Dantrolene Hepatitis

Publisher Website
Google Scholar
Abstract
DANTROLENE SODIUM is a new orally administered hydantoin derivative that is useful in control of skeletal muscle spasticity.1,2Known adverse effects include drowsiness, dizziness, nausea, vomiting, diarrhea, headache, and general malaise. To date, there have been no published reports of severe hepatic toxicity in association with the drug,3although minor abnormalities of liver function have been observed in a sizeable percentage of recipients.4,5Recently, the drug company has changed the package insert to warn of potential hepatic toxicity. We report a patient with dantrolene hepatitis who had deep jaundice. Report of a Case A 38-year-old woman who had had weakness and spasticity of her legs for four years was considered to have multiple sclerosis. In April 1974, dantrolene sodium therapy was started and was gradually increased to a dosage of 400 mg/day, which was continued until Aug 13, 1974. The only other drugs she was taking were cod

This publication has 2 references indexed in Scilit: